Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04355143 · ClinicalTrials.gov registry record · Phase 2
Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT04355143 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 93 participants.
The verdict
NCT04355143, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm). Importantly, this adaptive trial design allows for patients in either study arm to receive other investigational drugs for COVID-19 as new science emerges.
Interventions
- DRUG Colchicine Tablets
- OTHER Current care per UCLA treating physicians
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2021-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04355143
The ClinicalTrials.gov registry entry for NCT04355143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Colchicine Tablets is the first listed.
NCT04355143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04355143 about?
NCT04355143 is a clinical study titled "Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)". Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm). Importantly, this adaptive trial design allows for patients in either study arm to receive other investigational d...
What is the current status of trial NCT04355143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2020-05-01. Estimated completion is 2021-07-21.
What interventions are being tested in trial NCT04355143?
The interventions under investigation include: Colchicine Tablets (DRUG), Current care per UCLA treating physicians (OTHER).
Who is sponsoring clinical trial NCT04355143?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.